Research Paper Volume 11, Issue 18 pp 7442—7456

Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer

Figure 5. Genetic alterations in FOXA1 and clinicopathological parameters. Based on clinical pathology parameters, the expression profile of FOXA1 was expressed in the PAM50 breast cancer subtype using 5861 patients in bc-GenExMiner 4.0. A globally significant difference between the groups was assessed by Welch's t-test to generate p-values, as well as the Dunnett-Tukey-Kramer test.